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Abstract
Background: Previous studies in our lab have identified Pre-B-cell colony enhancing factor (PBEF)
as a novel biomarker in acute lung injury (ALI). The molecular mechanism of PBEF involvement in
the pathogenesis of ALI is still incompletely understood. This study examined the role of PBEF in
regulating pulmonary alveolar epithelial cell IL-8 expression and permeability.
Methods: Human pulmonary alveolar epithelial cells (cell line and primary cells) were transfected
with human PBEF cDNA or PBEF siRNA and then cultured in the presence or absence of TNFα.
PBEF and IL-8 expression were analyzed by RT-PCR and Western blotting. In addition, changes in
pulmonary alveolar epithelial and artery endothelial cell barrier regulation with altered PBEF
expression was evaluated by an in vitro cell permeability assay.
Results:  Our results demonstrated that, in human pulmonary alveolar epithelial cells, the
overexpression of PBEF significantly augmented basal and TNFα-stimulated IL-8 secretion by more
than 5 to 10-fold and increased cell permeability by >30%; the knockdown of PBEF expression with
siRNA significantly inhibited basal and TNFα-stimulated IL-8 secretion by 70% and IL-8 mRNA
levels by 74%. Further, the knockdown of PBEF expression also significantly attenuated TNFα-
induced cell permeability by 43%. Similar result was observed in human pulmonary artery
endothelial cells.
Conclusion: These results suggest that PBEF may play a vital role in basal and TNFα-mediated
pulmonary inflammation and pulmonary epithelial barrier dysfunction via its regulation of other
inflammatory cytokines such as IL-8, which could in part explain the role of PBEF in the
susceptibility and pathogenesis of ALI. These results lend further support to the potential of PBEF
to serve as a diagnostic and therapeutic target to ALI.
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Background
Acute lung injury (ALI) is characterized by pulmonary
inflammation, non-cardiogenic edema, and severe sys-
temic hypoxemia. Acute respiratory distress syndrome
(ARDS) is the severe form of ALI [1,2]. One of the earliest
manifestations of ALI is a diffuse intense inflammatory
process and damage to both endothelial and epithelial
cell barriers, resulting in marked extravasation of vascular
fluid into the alveolar airspace [3]. A number of inflam-
matory cytokines including tumor necrosis factor-alpha
(TNFα) and interleukin 8 (IL-8) can induce or aggravate
the inflammation of endothelial and epithelial cells, lead-
ing to this barrier dysfunctions [4]. The mortality and
morbidity of ALI/ARDS remain high since the etiology
and molecular pathogenesis are still incompletely under-
stood.
Our previous study, based on extensive microarray gene
expression profiling in canine, murine, and human ALI,
revealed pre-B-cell-colony-enhancing factor (PBEF) as a
significantly upregulated gene [5]. Analysis of single
nucleotide polymorphisms (SNPs) in the PBEF gene prox-
imal promoter region indicated that a GC haplotype had
a higher risk of ALI while a TT haplotype may have a lower
risk of ALI [5]. Our findings were confirmed and extended
by Bajwa et al [6], who showed that the PBEF T-1001G
variant allele and related haplotype are associated with
increased odds of developing ARDS and increased hazard
of intensive care unit mortality among at-risk patients. In
contrast, the C-1543T variant allele and related haplotype
are associated with decreased odds of ARDS among
patients with septic shock and better outcomes among
patients with ARDS. In a mechanistic study, we found that
PBEF is critically involved in thrombin-induced lung
endothelial cell barrier dysregulation [7].
The objective of this study was to further elucidate the role
of PBEF in pulmonary epithelial cell inflammation and
barrier regulation since impaired alveolar epithelial fluid
transport is also a characteristic feature in patients with
ALI and has been associated with increased morbidity and
mortality [4]. Using A549 human pulmonary alveolar epi-
thelial cells and primary bronchial airway epithelial cells,
we assessed the effect of PBEF knockdown with PBEF-spe-
cific silencing RNA (siRNA) and the effect of PBEF overex-
pression on TNFα-mediated IL-8 production and on
cellular barrier function. Effect of the altered PBEF expres-
sion on basal or TNFα stimulated primary human pulmo-
nary artery endothelial cells permeability was also
examined to indirectly validate the similar results in the
A549 cell line. Study of the role of PBEF in TNFα-medi-
ated pulmonary cell IL-8 production and resultant barrier
dysfunctions may help elucidate the molecular mecha-
nisms underlying the role of PBEF in the susceptibility
and pathogenesis of ALI.
Methods
Materials
Rabbit anti-human IL-8 polyclonal antibody (Cat. No. sc-
7922, Santa Cruz, California, USA) and mouse anti-
human β-actin monoclonal antibody (Cat. No. A1978)
were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Rabbit anti-human PBEF polyclonal antibody was from
Bethyl Laboratories, Inc. (Cat. No. A300-372A, Mont-
gomery, TX, USA). Total mouse lung RNA was from Strat-
agene (Cat. No. 736511, La Jolla, CA, USA). Recombinant
human TNFα (Cat. No. 210-TA) was from R&D Systems
Inc. (Minneapolis, MN, USA). Superscript III Reverse
Transcriptase (Cat. No. 18080044), Platinum Taq DNA
polymerase (Cat. No. 10966018) was from Invitrogen
(Carlsbad, CA, USA). Tricine was purchased from the
Sigma-Aldrich (Cat. No. T0377, St. Louis, MO, USA).
Sources of other key reagents are specified in the relevant
text.
Cell culture
Human A549 cells, a lung carcinomatous type II alveolar
epithelial cell line, were obtained from ATCC (Cat. No.
CCL-185™, Manassas, VA) and maintained in a Dul-
becco's Modified Eagle's Medium supplemented with
10% fetal bovine serum, 2 mM glutamine, and penicillin/
streptomycin. Primary human lung small airway epithe-
lial cells (Cat. No. CC-2547) were obtained from Lonza
(Walkersville, MD, USA) and maintained in a small air-
way epithelial cell basal medium (Cat. No. CC-3119) with
Supplement & Growth factors (Cat. No. CC-4124). Pri-
mary human pulmonary artery endothelial cells (HPAEC,
Cat. No. CC-2530) were obtained from Cambrex Bio Sci-
ence Inc. (Walkersville, MD, USA) and maintained in
EGM™-2 Endothelial Cell Medium-2 (Cat. No. CC-4176).
All cells were cultured at 37°C in a humidified atmos-
phere of 5% CO2, 95% air. Cells from each primary flask
were detached with 0.05% trypsin, resuspended in fresh
culture medium, and seeded into 6-well plates for West-
ern blot and RT-PCR analysis or seeded into the culture
inserts for in vitro cell permeability assays.
Transfection of PBEF siRNA into human A549 cells, 
primary human lung small airway epithelial cells and 
primary HPAEC
PBEF stealth siRNA was designed based on the human
PBEF cDNA reference sequence (NM_005746.1) using the
BLOCK-iT™ RNAi Designer (Invitrogen, Carlsbad, CA,
USA). Using GFP-labeled non-specific siRNA, we first
optimized the conditions for human A549 cells transfec-
tion and achieved >90% transfection efficiency using the
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA). To transfect PBEF stealth siRNA into human A549
cells, cells were seeded for 24 h in the regular growth
medium (without antibiotics) so that they would be 80–
90% confluent at the time of transfection. For each trans-Journal of Inflammation 2008, 5:15 http://www.journal-inflammation.com/content/5/1/15
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fection in 24-well plates, 50 pmol PBEF stealth siRNA was
diluted in 50 μl Opti-MEM I without serum and gently
mixed with 1 μl Lipofectamine 2000 diluted in the 50 μl
Opti-MEM I (Invitrogen, Cat. 31985-062). After incuba-
tion for 15 min at room temperature, PBEF stealth siRNA
and Lipofectamine 2000 complexes were added to each
well. Cell culture plates were gently mixed by rocking back
and forth. The amount of PBEF stealth siRNA and Lipo-
fectamine 2000 were adjusted according to the different
sizes of cell culture plates. Transfected cells were further
incubated at 37°C for 24–48 h until treatment with TNFα
before intended assays were carried out. Primary human
lung small airway epithelial cells were similarly trans-
fected. Transfection of PBEF siRNA into HPAEC was per-
formed as previously described by Ye et al [7].
Preparation and expression of the PBEF-overexpressing 
construct pCAGGS-hPBEF
A human PBEF (hPBEF) coding cDNA was amplified from
A549 cell total RNA by RT-PCR using the following primer
pair designed according to the reference human PBEF
mRNA sequence (NM_005746.2): forward primer, 5'-
TTAGAATTCGCCACCATGCCTGCGGCAGAAGCC-3'and
reverse primer, 5'-TTAGAATTCTTAATGGTGATGGTGAT-
GATGCAAATGATGTGCTGCTTCCAGTTC-3'. The regular
bold letters indicate the optimized Kozac sequence. The
bold italic letter part is His tag sequence. The underlined
sequences are EcoRI adaptors. The amplified human PBEF
cDNA was digested with EcoRI and subcloned into the
unique EcoRI site of pCAGGS vector, which was provided
by Dr. Deyu Fang (Department of Molecular Microbiol-
ogy and Immunology, University of Missouri-Columbia).
After the cloning, pCAGGS-hPBEF was sequence-verified.
In this construct, human PBEF expression was driven by a
chicken beta-actin/rabbit beta-globin hybrid promoter
(AG) with an enhancer from the human cytomegalovirus
immediate early promoter (CMV-IE). Overexpression of
PBEF in A549 cells and HPAEC was carried out by a tran-
sient transfection of pCAGGS-hPBEF. Briefly, one day
before transfection, A549 cells or HPAEC were plated in 6-
well plate at 5 × 105 cells/well in 2 ml of growth medium
without antibiotics. On the day of transfection, cells were
at 95% confluence. For each well, 4 μg plasmid DNA was
transfected using Lipofectamine 2000 according to the
suppliers' instruction. Cell medium and cell lysate pro-
teins were harvested at 48, 72 and 96 hours after the trans-
fection for western blotting analyses of IL-8, PBEF and β-
actin protein levels in A549 cells. pCAGGS-hPBEF or
pCAGGS transfected HPAEC were used only for the assess-
ment of cell permeability.
Isolation of RNA and RT-PCR analysis
Total RNA was isolated from A549 cells with TRIZOL
solution (Cat. No. 15596-018, Invitrogen, Carlsbad, CA,
USA) according to the supplier's instructions. RT-PCR was
performed using Invitrogen RNA PCR kit (Superscript III,
18080-044) with the following procedures: 1 μg total
RNA was reverse transcribed with random primer at 50°C
for 1 h followed by 70°C for 15 min and 4°C for 5 min in
a 20 μl reaction volume. Each PCR reaction from the
cDNA template (2 μl RT product) was performed using
gene specific primers (Table 1) at 94°C for 3 min, then 32
cycles at 94°C for 1 min, 55°C for 1 min and 72°C for 1
min, followed by 72°C for 7 min for the final extension.
β-actin was used as a house-keeping gene control. PCR
products were separated on a 1.5% agarose gel and
stained by Ethidium Bromide (0.5 μg/ml). The band
image was acquired using an Alpha Imager and analyzed
by the AlphaEase™ Stand Alone Software (Alpha Innotech
Corp., San leandro, CA, USA).
Western blotting
Western blot analysis was performed following the proto-
col of Bio-Rad Company. Briefly, after washing with PBS,
cells were lysed with 500 μl of cell lysis buffer containing
10 mM Tris (pH 7.4), 1% Triton X-100, 0.5% Nonidet P-
40, 150 mM NaCl, 1 mM EDTA, 0.2 mM EGTA, 0.2 mM
vanadate, 0.2 mM PMSF, and 0.5% protease inhibitor
cocktail. Total cell lysates were cleared by centrifugation
and boiled with the same amount of 4× SDS sample
buffer for 5 min. Total protein of cell lysates was quanti-
fied using the BCA Protein Assay Kit (Pierce Biotechnol-
ogy, Inc., Rockford, IL, USA). An equal amount of total
protein from each sample was then subjected to 16.5%
Tris/tricine polyacrylamide gel electrophoresis. The sepa-
rated proteins were transferred to PVDF membranes by
electrotransfer. The blots were subsequently blocked with
5% bovine serum albumin in PBS containing 0.1% Tween
20 (TBS-T) at room temperature for 1 h and then incu-
bated at 4°C overnight with primary antibodies of inter-
est. After washing three times for 10 min with TBS-T, the
membrane was incubated with horseradish-peroxidase-
linked secondary antibodies of interest at room tempera-
ture for 1 h. The blots were then visualized with the ECL
Table 1: Primers and products sizes
Products 5' Primers 3' Primers Size (bp) Accession No.
IL-8 ATGACTTCCAAGCTGGCCGT CCTCTTCAAAAACTTCTCCACACC 297 NM_000584
PBEF AAGCTTTTTAGGGCCCTTTG AGGCCATGTTTTATTTGCTGACAAA 319 NM_005746
β-actin CAAACATGATCTGGGTCATCTTCTC GCTCGTCGTCGACAACGGCTC 487 NM_001101Journal of Inflammation 2008, 5:15 http://www.journal-inflammation.com/content/5/1/15
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Western blot detection system (Cat. No. RPN2106, Amer-
sham Bosciences, Buckinghamshire, UK). The same mem-
brane was re-probed with an anti-human β-actin
antibody. β-actin was used as an internal control. Band
density on Western blot images was used as a measure of
assayed protein level. The band image was acquired using
an Alpha Imager and analyzed by the AlphaEase™ Stand
Alone Software.
In Vitro Cell Permeability Assay
In Vitro Cell Permeability Assay was carried out according
to the protocol of the CHEMICON in vitro Vascular Perme-
ability Assay kit (Cat. No. ECM640, Millipore, Billerica,
MA, USA). Briefly, cells were seeded to the culture inserts
of permeability chambers (1.0 × 106 cells/ml) that were
coated with collagen. Then, cells were incubated in 37°C
and 5% until a monolayer was formed. After TNFα (Cat.
No. 636-R1, R&D systems, Minneapolis, MN, USA) was
added, cells were incubated for another 18 hours at 37°C
and 5% CO2 in the tissue culture incubator. Finally, 150
μl of FITC-Dextran was added to each insert for 5 min at
room temperature, and then 100 μl of the solution in the
bottom chamber was transferred to a 96-well plate. The
plate was read in a TriStar Multimode Reader (LB 941,
Berthold Technologies GnbH & Co. KG, Bad Wildbad,
Germany) at wavelengths of 485 and 530 nm. Reagent
control wells were treated with basal medium and growth
medium only. Blank inserts without cells plated were also
included as controls.
Statistical analysis
Statistical analyses were performed using SigmaStat (ver
3.5, Systat Software, Inc., San Jose, CA, USA). Results are
expressed as mean ± standard deviation (SD) of four sam-
ples from at least two independent experiments. Stimu-
lated samples were compared with controls by unpaired
Student's t test. P < 0.05 was considered statistically signif-
icant.
Results
Dose-response and time-course of TNFα induced IL-8 
protein expression in A549 cells
In order to examine the role of PBEF in human pulmonary
alveolar epithelial cell inflammation, we began by quan-
tifying TNFα induced IL-8 protein expression within A549
cells. We first determined the dose-response and time-
course of TNFα induced IL-8 protein expression in A549
cells in our experimental conditions. The results (Figure 1,
panel A) demonstrate that TNFα treatment for 24 h signif-
icantly induced IL-8 secretion in A549 cells in a dose-
dependent manner up to the highest tested concentration
of TNFα (25 ng/ml). Within the cell lysate, IL-8 level was
also increased with TNFα treatment but was not dose-
dependent within the tested dose range. Secreted IL-8 lev-
els was also significantly increased in a time-dependent
manner after TNFα (15 ng/ml) treatment compared with
control group (Figure 1, panel B), especially at 6, 18, and
24 h time points. Again, cell lysate IL-8 levels were
increased with treatment but not in a time dependent
manner. These data indicate that TNFα significantly
increased IL-8 secretion in dose-dependent and time-
dependent manners in A549 cells in our experimental
conditions. The 24 h time point and 15 ng/ml of TNF α
dosage were selected for subsequent experiments.
Dose-response and time-course of TNFα induced PBEF 
protein expression in A549 cells
After a pilot experiment provided evidence that PBEF
expression could be induced by TNFα treatment in A549
cells (data not shown), we sought to determine the dose-
response and time-course to optimize the experimental
conditions of TNFα induced PBEF expression in A549
cells. In this dose-response experiment (Figure 2, panel
A), our results show that secreted PBEF level was increased
in a dose-dependent manner and cell lysate PBEF expres-
sion was significantly increased compared to control at all
dose treatments of TNFα tested [15 ng/ml TNFα treatment
vs. control: 1.17 ± 0.02 vs. 0.9 ± 0.005, n = 4, p < 0.05]. In
the time-course experiment (Figure 2, panel B), secreted
and intracellular PBEF protein expression continued to
increase over the 24 h of TNFα treatment [TNFα treatment
vs. control at 24 h: 1.56 ± 0.04 vs. 0.837 ± 0.03, n = 4, p <
0.01]. The dose-response and time-course of TNFα medi-
ated PBEF expression in A549 cells are similar to those of
IL-8.
TNFα induction of IL-8 and PBEF expression at their 
mRNA levels in A549 cells
To investigate whether TNFα augments IL-8 and PBEF
expression at their mRNA levels in A549 cells, we per-
formed a semi-quantitative RT-PCR analysis of IL-8 and
PBEF mRNA levels in TNFα induced A549 cells. As pre-
sented in Figure 3, IL-8 and PBEF mRNA levels in TNFα
treated A549 cells were significantly increased compared
to the control groups (IL-8 mRNA expression: 0.89 ± 0.04
vs. 0.42 ± 0.05, n = 4, p < 0.01; PBEF mRNA expression:
0.5 ± 0.04 vs. 0.37 ± 0.025, n = 4, p < 0.05; respectively).
Knockdown of PBEF protein and mRNA expression by 
PBEF stealth siRNA in A549 cells
We first performed a pilot experiment to demonstrate that
PBEF siRNA could in fact knock down PBEF expression in
A549 cells before determining the optimal time course
and dose response of PBEF stealth siRNA for the inhibi-
tion of PBEF protein expression in A549 cells (data not
shown). The 48 h time point and 50 nm dosage were
selected for the intended experimentation. In the baseline
condition without the TNFα treatment (Figure 4, Panels A
and B), PBEF siRNA significantly knocked down PBEF
protein expression in A549 cells [siRNA vs. control: 1135Journal of Inflammation 2008, 5:15 http://www.journal-inflammation.com/content/5/1/15
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Figure 1 (see legend on next page)
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± 33 vs. 3253 ± 624, n = 4, p < 0.01]. Scrambled RNA
(scRNA) and reagent alone had no effect on PBEF protein
expression. PBEF-specific siRNA had no effect on the pro-
tein expression level of β-actin, a house-keeping gene serv-
ing as a control. In the + TNFα treatment group (Figure 4,
Panels A and B), PBEF protein level in the scRNA group
had no significant change (scRNA vs. control: 7246 ± 856
vs. 6440 ± 889, n = 4, NS), while PBEF protein level in the
siRNA group was significantly lower than in the control
(siRNA vs. control: 1926 ± 415 vs. 7246 ± 856, n = 4, p <
0.01). Figure 4, panels C and D, illustrates the expected
effect of PBEF siRNA on significantly inhibiting PBEF
mRNA expression in both the baseline and treated groups.
These results indicate that PBEF-specific siRNA can signif-
icantly reduce both PBEF protein and mRNA production
in both baseline and TNFα activated A549 cells.
PBEF silencing attenuated TNFα-induced increases in IL-8 
secretion and IL-8 mRNA expression within A549 cells
Based on an efficient knock down of PBEF in A549 cells
with PBEF siRNA, we next evaluated the effect of PBEF
knockdown on the TNFα-induced increases in IL-8 secre-
tion and IL-8 mRNA level from A549 cells. In Figure 5
(panels A and B) PBEF silencing significantly decreased IL-
8 secretion from A549 cells in TNFα-stimulated condi-
tions compared to the control group (siRNA vs. control:
2807.69 ± 161.2 vs. 9178.58 ± 512.64, n = 4, p < 0.01),
while secreted IL-8 level in the scRNA group had a small
and statistically insignificant change relative to the control
group (scRNA vs. control: 8808.37 ± 400.52 vs. 9178.58 ±
512.64, n = 4, NS). Further, Figure 5 (panels C and D)
demonstrates that PBEF silencing decreased IL-8 mRNA
expression levels in the baseline (-TNFa) group (siRNA vs.
control: 886.17 ± 190 vs. 3718.27 ± 360, n = 4, p < 0.01)
as well as the treatment (+TNFα) group (siRNA vs. con-
trol: 2128.78 ± 96 vs. 3255.42 ± 107, n = 4, p < 0.05).
These results indicate that PBEF is involved in IL-8 expres-
sion and secretion under both baseline and TNFα-stimu-
lated conditions within the A549 cells.
PBEF silencing attenuated TNFα-induced increases in IL-8 
secretion and PBEF protein expression in lung primary 
small airway epithelial cells
To further confirm the above results, we also investigated
PBEF effects on TNFα-induced IL-8 secretion in primary
human lung small airway epithelial cells. In Figure 5 (pan-
els E and F), PBEF silencing is shown to decrease IL-8
secretion in TNFα-stimulated conditions (siRNA vs. con-
trol: 10609.50 ± 4086.65 vs. 28801.42 ± 1235.48, n = 4,
p < 0.01). In contrast, scRNA demonstrated no difference
from control. These results indicate that PBEF is also
involved in IL-8 expression and secretion in TNFα
induced conditions in primary human lung small airway
epithelial cells.
PBEF over-expression augmented IL-8 secretion from A549 
cells
Since PBEF silencing could decrease TNFα-induced IL-8
secretion from A549 cells, the next experiments evaluated
whether PBEF over-expression would augment IL-8 secre-
tion from A549 cells. Similarly treated non-transfected
A549 cells served as the control. In Figure 6 (panels A and
B), the over-expression of PBEF in A549 cells transiently
transfected with pCAGGS-hPBEF was achieved in both the
secreted PBEF levels (transfected vs. control: 29712.81 ±
16259.85 vs. 948.75 ± 136.7, n = 4, p < 0.01) and in cell
lysate PBEF levels (transfected vs. control: 70666.3 ±
22445.3 vs. 13519.15 ± 5745.44, n = 4, p < 0.01). PBEF
over-expression significantly increased IL-8 secretion from
A549 cells compared to control group (transfected vs.
control: 111548.4 ± 84104.5 vs. 1034 ± 212.5, n = 4, p <
0.01). These findings suggest that PBEF has a direct effect
on IL-8 secretion from A549 cells. Further, Figure 6 (pan-
els C and D) demonstrates that PBEF over-expression also
significantly augmented TNFα-induced IL-8 secretion
from A549 cells compared to control group (transfected
vs. control: 604423.1 ± 82477.6 vs. 350227.4 ± 19794.1)
and IL-8 production in cell lysate in A549 cells compared
to control group (transfected vs. control: 420519.4 ±
49539.8 vs. 224406.9 ± 45849.1). Those result further
confirmed that PBEF has a very important role in TNFα-
induced IL-8 secretion in A549 cells.
Dose-response and time-course of TNFα-induced IL-8 protein expression in A549 cells Figure 1 (see previous page)
Dose-response and time-course of TNFα-induced IL-8 protein expression in A549 cells. A. Dose-response. The 
top panel illustrates a typical western blotting image of IL-8 and β-actin protein detections. After starving for serum overnight, 
A549 cells were stimulated with different doses of TNFα as indicated for 24 hours. Equal amount of total protein from each 
sample was separated by 16.5% SDS-PAGE and immunodetected by the western blotting using anti-human IL-8 or β-actin anti-
bodies. Middle panel-Quantitation of secreted IL-8 level by densitometric analysis. Results from each group are presented as 
mean ± SD of 4 samples from two separate experiments. Bottom panel-Quantitation of cell lysate IL-8 level by densitometric 
analysis. **p < 0.01 vs. control (0 ng.ml TNFα). B. Time-course. Top panel-Representative western blotting image of IL-8 and 
β-actin protein detections. After starving for serum overnight, A549 cells were stimulated with TNFα (15 ng/ml) for different 
time (h) as indicated. Middle panel-Quantitation of secreted IL-8 protein level by densitometric analysis. Bottom panel-Quanti-
tation of cell lysate IL-8 protein level by densitometric analysis. *p < 0.05 and **p < 0.01 vs 0 dosage of TNFα or 0 h control.Journal of Inflammation 2008, 5:15 http://www.journal-inflammation.com/content/5/1/15
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Figure 2 (see legend on next page)
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PBEF expression affected cell permeability in A549 cells 
and human pulmonary artery endothelial cells (HPAEC)
To assess whether PBEF expression affected lung alveolar
epithelial cell and HPAEC permeability, we performed in
vitro monolayer cell permeability assays in A549 cells and
HPAEC transfected with PBEF stealth siRNA or pCAGGS-
hPBEF in the presence and absence of TNFα treatment.
Controls were either scRNA or reagent vehicle without the
vector, respectively. In Figure 7A, PBEF siRNA significantly
decreased TNFα-induced permeability in A549 cells com-
pared to the TNFα treated controls (siRNA vs. control:
15476.09 ± 577.35 vs. 27065 ± 563.04, n = 4, p < 0.01).
Scrambled RNA had no effect on the TNFα-induced cell
permeability in A549 cells. Under baseline (-TNFα) con-
ditions, no differences in cell permeability were detected.
These results indicate PBEF siRNA significantly attenuated
the TNFα-induced barrier-disruption within the epithelial
cells. To validate our observation in A549 cells, we per-
formed the same experiment in a primary HPAEC. As dis-
played in Figure 7C, similar observations were obtained in
HPAEC, whose cell permeability level in the PBEF siRNA
group was significantly decreased compared to the TNFα
alone treatment (13325 ± 1527.2 vs. 30850 ± 937.5 rela-
tive fluorescence units, n = 4, **P < 0.01). Scrambled RNA
had no effect on the TNFα induced cell permeability in
both A549 cells and HPAEC (Figure 7C). In Figure 7B,
PBEF overexpression significantly promoted TNFα-
induced A549 cell permeability level in the pCAGGS-
hPBEF transfected group compared to the control groups
(overexpression vs. control: 29156.09 ± 113.57 vs.
18570.4 ± 84.85, n = 4, p < 0.01). Similar observations
were obtained in HPAEC cells (Figure 7D), whose cell per-
meability level in the PBEF overexpression group is signif-
icantly increased compared to the TNFα alone treatment
(36955 ± 306.4 vs. 26331 ± 300.69 relative fluorescence
units, n = 4, **P < 0.01). Scrambled RNA had no effect on
the TNFα induced cell permeability in both A549 and
HPAEC cells (Figure 7A and 7C). Even under baseline (-
TNFa) conditions, overexpressing PBEF significantly
increased cell permeability in A549 cells (over-expression
vs. control: 12506.14 ± 141.42 vs.2537.4 ± 154.27, n = 4,
p < 0.01) and HPAEC (22336.45 ± 70.71 vs.13675.4 ±
117.85 relative fluorescence units, n = 4, *P < 0.05). These
results indicate that overexpression of PBEF augmented in
vitro lung epithelial cell permeability under both the base-
line and TNFα-induced conditions.
Discussion
Our findings demonstrate that the modulation of PBEF
expression resulted in parallel changes in TNFα-mediated
IL-8 production and secretion as well as alveolar epithelial
cell permeability. These results provide new insight into
the role of PBEF in the inflammatory pathways and func-
tional abnormalities associated with ALI.
There is considerable experimental and clinical evidence
that pro-inflammatory cytokines play a major role in the
pathogenesis of ALI/ARDS from inflammatory causes,
such as sepsis, pneumonia, aspiration, and shock [8], as
well as from mechanical stress [9-11]. The landmark ARD-
Snet clinical trial found that a lung-protective ventilatory
strategy reduces mortality by 22% in patients with ALI, a
result that in part may be ascribed to the marked reduc-
tion in the concentration of pro-inflammatory cytokines
released into the airspaces of the injured lung [12,8].
TNFα and IL-8 are among important early mediators of
ALI [4]. It has been shown that TNFα is present in
increased amounts in the bronchoalveolar lavage fluid
(BALF) of patients with ARDS [13], in the serum during
the onset of sepsis-induced lung injury [14], and acutely
increases in both serum and BALF when changing from a
lung protective to non-protective ventilation strategy [9].
Increasing TNFα biological activity has been demon-
strated over the first week of ARDS and there are direct
relationships between the molar ratio of TNFα/soluble
TNF-receptor in the BALF and severity of ALI (lung com-
pliance and severity of hypoxemia) [13]. The role of TNFα
in pulmonary pathophysiology has been well studied,
and includes induction of cellular inflammatory reac-
tions, enhancement of oxidative stress, and increased
expression of various proinflammatory molecules [15].
Among the TNFα induced pro-inflammatory cytokines,
IL-8 is regarded as one of the most important mediators in
Dose-response and time-course of TNFα induced PBEF protein expression in A549 cells Figure 2 (see previous page)
Dose-response and time-course of TNFα induced PBEF protein expression in A549 cells. A. Dose-response. The 
top panel is a typical western blotting image of PBEF and β-actin protein detections. After starving for serum overnight, A549 
cells were stimulated with different doses of TNFα, as indicated, for 24 hours. Equal amount of total cell lysate protein from 
each sample was separated by 10% SDS-PAGE and immunodetected by the western blotting using anti-human PBEF or β-actin 
antibodies. Middle panel-Quantitation of secreted PBEF level by densitometric analysis. Results from each group are presented 
as mean ± SD of 4 samples from two separate experiments. The bottom panel is the quantitation of cell lysate PBEF protein 
level by densitometric analysis. B. Time-course. Top panel-Representative western blotting image of PBEF and β-actin protein 
detections. After starving for serum overnight, A549 cells were stimulated with TNFα (15 ng/ml) for different time (h) as indi-
cated. Lower panel-Quantitation of cell lysate PBEF protein level by densitometric analysis. *p < 0.05 and **p < 0.01 vs 0 dos-
age of TNFα or 0 h control.Journal of Inflammation 2008, 5:15 http://www.journal-inflammation.com/content/5/1/15
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the pathogenesis of ARDS. In BALF, IL-8 levels were signif-
icantly increased in patients with ARDS and correlated
with the development of ARDS in at-risk patients [16,17].
IL-8 has been identified as one of biomarkers of ALI/
ARDS mortality [18]. In fact, IL-8 was first purified and
molecularly cloned as a neutrophil chemotactic factor
from lipopolysaccharide-stimulated human mononuclear
cell supernatants [19]. Since then, studies of models of
acute inflammation have established IL-8 as a key media-
tor in neutrophil mediated acute inflammation [20]. In
acid aspiration- and endotoxemia-induced ARDS in rab-
bits, IL-8 is produced in the lungs [21,22]. In both mod-
els, the abrogation of IL-8 activity reduces neutrophil
infiltration as well as tissue damage. It was demonstrated
that TNFα mediated IL-8 production can suppress neu-
trophil apoptosis [23] and thus potentially prolong neu-
trophil migration into the lungs and damage to lung
tissues, including alveolar epithelial barrier function [24].
Effect of TNFα treatment on the mRNA expression of IL-8 and PBEF in A549 cells Figure 3
Effect of TNFα treatment on the mRNA expression of IL-8 and PBEF in A549 cells. A. A representative gel image 
of IL-8, PBEF and β-actin mRNA detections. After starving for serum overnight, A549 cells were stimulated with TNFα (15 ng/
ml) for 4 h. Total cell RNA was reverse-transcribed, amplified by PCR using the gene specific primers (Table 1), separated by 
1.5% agarose electrophoresis, and visualized with ethidium bromide. B. Quantitation of IL-8 and PBEF mRNA levels by densito-
metric analysis. Results from each group are presented as mean ± SD of 4 samples from two separate experiments. *p < 0.05 
and **p < 0.01 vs 0 dosage of TNFα or control.
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Our data in this study indicate that TNFα significantly
induces PBEF expression at both the mRNA and protein
levels in A549 cells (Figures 2, 3, 4, 5), suggesting that
PBEF may be an intermediate target of TNFα involved in
the inflammatory process during the pathogenesis of ALI.
The knockdown of PBEF expression by PBEF siRNA signif-
icantly blunted TNFα-stimulated IL-8 secretion and its
production in A549 cells (Figures 6, 7), and PBEF-overex-
pression augmented IL-8 secretion from A549 cell (Figure
7). These results support the concept that PBEF may be an
inflammatory signal transducer of TNFα or other inflam-
matory stimuli to regulate the synthesis of IL-8 or other
inflammatory cytokines. These conclusions can be corrob-
orated by evidence in non-lung tissue studies. PBEF silenc-
ing has been shown to prevent the suppression of
neutrophil apoptosis caused by TNFα, IL-8 and other
mediators [25]. In addition, PBEF gene expression is up-
regulated in severely infected fetal membranes [26].
Inflammatory stimuli in fetal membranes inducing NF-κB
and AP-1 have been shown to up-regulate PBEF [27]. The
recombinant human PBEF treatment of amnion-like epi-
thelial cells and fetal membrane explants significantly
PBEF stealth siRNA-mediated silencing of PBEF protein and mRNA expression in A549 cells Figure 4
PBEF stealth siRNA-mediated silencing of PBEF protein and mRNA expression in A549 cells. A. Representative 
western blotting image of PBEF protein detections. After starving for serum overnight, A549 cells were transfected with the 
control (C), scrambled siRNA (Sc), or 50 nmolar PBEF stealth siRNA (Si) for 48 h before treatment without or with TNFα (15 
ng/ml) for 24 hours. Cell lysate PBEF and β-actin protein were immunodetected as described. B. Quantitation of PBEF protein 
levels by densitometric analysis. A549 Cell lysate PBEF protein levels in various treatments were quantified by densitometric 
analysis. **p < 0.01. C. A representative RT-PCR gel image of PBEF and β-actin mRNA detections. A549 cells were grown and 
transfected with the PBEF siRNA and other controls as described above and then treated without or with TNFα (15 ng/ml) for 
4 hours. Total cell RNA was reverse-transcribed, amplified by PCR using gene specific primers (Table 1), separated by 1.5% 
agarose electrophoresis and visualized with ethidium bromide. D. Quantification of PBEF mRNA level by densitometric analysis. 
**p < 0.01 vs. control.
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increased IL-6 and IL-8 expression [28]. Considered
together, PBEF could play a critical role as an inflamma-
tory cytokine during the pathogenesis of ALI.
Both endothelial and epithelial injuries were observed in
earlier ultrastructural studies of the lung in patients dying
with ALI secondary to sepsis [29,30]. Increased vascular
permeability and endothelial injury contribute to the pro-
found pathophysiological derangements in ALI [31,32]. If
Effects of PBEF knock down on IL-8 protein & mRNA expression in A549 cells (A-D) and in lung primary small airway epithelial  cells (E-F) Figure 5
Effects of PBEF knock down on IL-8 protein & mRNA expression in A549 cells (A-D) and in lung primary small 
airway epithelial cells (E-F). A. Representative western blotting image of secreted IL-8 protein detections. After starving for 
serum overnight, A549 cells were transfected with the vehicle control (C), scrambled siRNA (Sc), or PBEF stealth siRNA (Si) 
for 48 h before treatment without or with TNFα (15 ng/ml) for 24 hours. B. Quantitation of secreted IL-8 protein levels by 
densitometric analysis. **p < 0.01 vs. control. C. Representative RT-PCR gel image of IL-8 and β-actin mRNA detections. A549 
cells were grown and transfected with the PBEF siRNA and other controls as described above before treatment without or 
with TNFα (15 ng/ml) for 4 hours. Total cell RNA was reverse-transcribed, amplified by PCR using gene specific primers 
(Table 1), separated by 1.5% agarose electrophoresis and visualized with ethidium bromide. D. Quantitation of IL-8 mRNA 
level by densitometric analysis. **p < 0.01 vs. control. E. Representative western blotting images of cell lysate PBEF and 
secreted IL-8 protein detections. Lung primary small airway epithelial cells were transfected with control (C), PBEF stealth 
siRNA (Si), or scrambled RNA (Sc) for 48 h before treatment without or with TNFα (10 ng/ml) for 12 hours. PBEF in cell 
lysate and secreted IL-8 protein were immunodetected as described in Figures 1 and 2. F. Quantitation of IL-8 and PBEF pro-
tein levels by densitometric analysis. **p < 0.01 vs. control.
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the alveolar epithelium is also damaged, the change in
both endothelial and epithelial permeability could lead to
major alveolar flooding with high-molecular-weight pro-
teins, with prolonged changes in gas exchange, altered
compliance and a much higher likelihood of disordered
repair [33]. Normally, the lung alveolar epithelium forms
an extremely tight barrier that restricts the movement of
proteins and liquid from the interstitium into the alveolar
spaces. In ALI, impaired alveolar epithelial function in the
lungs is a marker of poor outcome in ALI [34]. A number
of inflammatory cytokines, including TNFα and IL-8, can
induce or aggravate the inflammation of endothelial and
epithelial cells, leading to their barrier dysfunctions [35].
In this study we have demonstrated (Figure 7) that the
TNFα stimulated increased in A549 cell permeability is
significantly attenuated by the knockdown of PBEF
expression by PBEF siRNA. Overexpression of PBEF
increased A549 cell permeability in both basal and TNFα
Effects of PBEF overexpression on IL-8 secretion and PBEF production in A549 cells Figure 6
Effects of PBEF overexpression on IL-8 secretion and PBEF production in A549 cells. A. Representative western 
blotting image of PBEF and IL-8 protein detections. After starving for serum overnight, A549 cells were transfected with con-
trol (C), overexpressing construct pCAGGS-hPBEF (E) or vector pCAGGS (V) for 48 hours. Medium IL-8 and PBEF, Cell lysate 
PBEF and β-actin proteins were immunodetected as described in Figure 1 and Figure 2. B. Quantitation of PBEF and IL-8 pro-
tein levels by densitometric analysis. **p < 0.01 vs. control. C. representative western blotting image of PBEF and IL-8 protein 
detections with or without TNFα (15 ng/ml) treatment. A549 cells were transfected with control (C), pCAGGS-hPBEF (E) or 
vector pCAGGS (V) for 48 hours, and then stimulated by TNFα (15 ng/ml) for another 12 hours. Medium IL-8 and PBEF, cell 
lysate PBEF and β-actin proteins were immunodetected as described in above. D. quantitation of PBEF and IL-8 protein levels 
by densitometric analysis. **p < 0.01 vs. control.
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induced conditions. These results suggest that PBEF may
have an important role in epithelial cell barrier regulation.
A549 cells are an alveolar Type II tumor epithelial cell
line. While the type II epithelial cell only covers 7% of the
alveolar surface area, it constitutes 67% of the epithelial
cell number within the alveoli [36], pointing to its bio-
chemical importance. The permeability increase of A549
cells in the TNFα-stimulated condition involves both
paracellular permeability, with gap formation visualized
by actin cytoskeleton staining, and basement membrane
permeability [37]. Since A549 cells usually do not form a
regular monolayer, we went to examine whether a similar
effect can be observed in a primary HPAEC, which forms
a typical monolayer. Indeed, we found that PBEF expres-
sion similarly affected the HPAEC permeability (Figure 7).
While an overexpression of PBEF results in an increased
basal permeability, knocking down PBEF expression
failed to alter the basal permeability both in A549 cells
and HPAEC. It is possible that in our study, transfection of
pCAGGS-PBEF engendered at least 3 fold higher PBEF
protein expression, but transfection of PBEF siRNA only
resulted in about 60% decrease of PBEF level, which
might explain the subdued effect of the latter in the basal
level. TNFα mediated effect may be partly due to its induc-
tion of IL-8 production. IL-8 has been demonstrated to
induce actin fiber rearrangement and intercellular gap for-
mation in endothelial cells [38]. IL-8 could have a similar
effect on epithelial barrier function. Our previous study
found that reductions in PBEF protein expression signifi-
cantly attenuated endothelial barrier dysfunction induced
by the potent edemagenic agent, thrombin, reflected by
reductions in transendothelial electric resistance [7]. Fur-
thermore, reductions in PBEF protein expression blunted
thrombin-mediated increases in Ca2+ entry, polymerized
actin formation, and myosin light chain phosphorylation
[7], events critical to the thrombin-mediated permeability
response [32]. Whether similar mechanisms account for
the attenuating effects of PBEF knockdown on TNFα-
induced epithelial and endothelial cell barrier dysfunc-
tion remains to be elucidated in future studies.
Conclusion
In summary, this study demonstrated that TNFα signifi-
cantly induced PBEF and IL-8 expression at both the
mRNA and protein levels in A549 cells. PBEF-overexpres-
sion augmented IL-8 secretion and epithelial cell permea-
bility in A549 cells, and the knockdown of PBEF
expression by PBEF siRNA significantly blunted TNFα-
stimulated IL-8 secretion and mRNA production and
attenuated TNFα-induced cell permeability of A549 cells.
Since inflammation and increased permeability is a hall-
mark of the pathogenesis of ALI, these results suggest that
PBEF may play a critical role as an inflammatory cytokine
in the dysregulation of alveolar epithelial cell barriers in
the pathogenesis of ALI. These results lend further support
to the potential of PBEF to serve as a diagnostic and ther-
apeutic target in future studies of lung injury.
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